• Hanall BioPharma’s third-quarter 2026 net profit rose 924.2% year over year to KRW 3.06 billion.
• Operating profit increased 265.1% from a year earlier to KRW 1.27 billion.
• Revenue fell 2.2% year over year to KRW 39.91 billion.
• Sequentially, operating profit dropped 77.2%; revenue declined 9.9%.
• Nine-month net results swung to a KRW 15.89 billion loss from a KRW 690 million profit a year earlier.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanall BioPharma Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261028800653), on October 28, 2026, and is solely responsible for the information contained therein.